Guizhou Sanli Pharmaceutical Co.,Ltd (SHA:603439)

Market Cap	5.06B +0.7%
Revenue (ttm)	1.68B -21.4%
Net Income	48.72M -81.3%
EPS	0.12 -81.4%
Shares Out	404.74M
PE Ratio	106.96
Forward PE	n/a
Dividend	0.06 (0.47%)
Ex-Dividend Date	Jun 26, 2025

Volume	10,490,700
Average Volume	7,076,138
Open	12.52
Previous Close	12.51
Day's Range	12.44 - 13.08
52-Week Range	10.49 - 14.32
Beta	0.76
RSI	66.86
Earnings Date	Apr 27, 2026

About SHA:603439

Guizhou Sanli Pharmaceutical Co.,Ltd, together with its subsidiaries, engages in the plantation, research, development, production, and sale of pharmaceutical products in China. The company offers respiratory system, tonic, gynecological, and orthopedic medications, as well as cardiovascular and cerebrovascular drugs, and other medicines. It also provides products in various dosage forms, including sprays, granules, capsules, pills, tablets, medicated wines, and ointments. The company was founded in 1995 and is based in Anshun, China.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1995
• Employees: 2,852
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 603439

Financial Performance

In 2025, SHA:603439's revenue was 1.70 billion, a decrease of -20.59% compared to the previous year's 2.14 billion. Earnings were 46.25 million, a decrease of -83.12%.